Scarica l'app Stockscreener
54.80
1.15%
0.6318
Precedente Chiudi:
$54.17
Aprire:
$54.21
Volume 24 ore:
172.40K
Relative Volume:
0.13
Capitalizzazione di mercato:
$5.30B
Reddito:
$7.50M
Utile/perdita netta:
$-383.17M
Rapporto P/E:
-11.65
EPS:
-4.7048
Flusso di cassa netto:
$-307.84M
1 W Prestazione:
+1.38%
1M Prestazione:
-0.81%
6M Prestazione:
+23.16%
1 anno Prestazione:
+84.18%
Intervallo 1D:
$53.84
$54.99
Intervallo di 1 settimana:
$53.62
$55.80
Portata 52W:
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
54.80 | 5.24B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
436.02 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.02 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.99 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.34 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE) - Insider Monkey
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Stock Price, Quote & Chart | XENON PHARMACEUTICALS INC (NASDAQ:XENE) - ChartMill
5 Best Performing Canadian Stocks So Far in 2026 - Insider Monkey
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown - Sahm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - AOL.com
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus - AD HOC NEWS
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
XENE: Azetukalner’s strong efficacy and novel mechanism set the stage for a major epilepsy market launch - TradingView
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares - Stock Titan
XENE Maintained by JP Morgan -- Price Target Raised to $80.00 - GuruFocus
Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan - Moomoo
Xenon anticipates AZK NDA in Q3 2026 amid launch timing at end of 2027 or early 2028 - MSN
Equities Analysts Set Expectations for XENE Q2 Earnings - MarketBeat
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway - Yahoo Finance
Insiders At Xenon Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - Moomoo
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative? - Yahoo Finance
Nan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $63 to $80.65 - Moomoo
Xenon Pharmaceuticals Q1 earnings call highlights - MSN
Xenon Pharmaceuticals Q1 Earnings Call Highlights - sharewise.com
Xenon Pharmaceuticals Maps Path After Standout XTOL-2 - TipRanks
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus - Yahoo Finance
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
Needham Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $78 - Moomoo
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $74 to $80.65 - Moomoo
Xenon Pharmaceuticals (XENE) Achieves Milestones Ahead of FDA Su - GuruFocus
Xenon Pharmaceuticals 1Q Rev $0.00 >XENE - Moomoo
William Blair Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $80.65 - Moomoo
Earnings call transcript: Xenon Pharmaceuticals Q1 2026 results show mixed signals - Investing.com Nigeria
Xenon Pharmaceuticals Q1 Loss Widens - Moomoo
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18 - marketscreener.com
Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission - ChartMill
Xenon Pharmaceuticals (XENE) deepens Q1 loss but amasses $1.34B cash war chest - Stock Titan
Xenon Pharmaceuticals: Q1 Earnings Snapshot - kare11.com
A seizure drug filing is next, but Xenon has 5 more Phase 3 studies running - Stock Titan
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & Headlines - Yahoo Finance
Xenon Reports Q1 2026 Financial Results and Provides Business Update - The Manila Times
Big cash raise and strong Phase 3 results headline Xenon (XENE) Q1 2026 - Stock Titan
Xenon Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Xenon Pharmaceuticals faces earnings test as launch nears - Investing.com UK
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Mar 13 '26 |
Sale |
55.23 |
1,410 |
77,867 |
7,069 |
| DiFabio Andrea | Chief Legal Officer |
Mar 13 '26 |
Sale |
55.23 |
1,342 |
74,112 |
7,301 |
| MORTIMER IAN | PRESIDENT & CEO |
Mar 13 '26 |
Sale |
55.23 |
7,308 |
403,584 |
19,923 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):